Burn Pain Market to Reach New Heights in Growth by 2034, DelveInsight Predicts
The Key Burn Pain Companies in the market include - Medical Developments International, Cumberland Pharmaceuticals, Janssen Research & Development, Cephalon, and others.
DelveInsight's 'Burn Pain Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Burn Pain, historical and forecasted epidemiology as well as the Burn Pain market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Burn Pain Market Report:
The Burn Pain market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In August 2024, MediWound Ltd. (Nasdaq: MDWD), a global leader in enzymatic therapeutics for tissue repair, announced that the U.S. Food and Drug Administration (FDA) has approved NexoBrid® (anacaulase-bcdb) for eschar removal in pediatric patients from newborns to 18 years old with deep partial- and full-thickness thermal burns. This approval expands NexoBrid's authorization for all age groups in the U.S., aligning with its approvals in the European Union and Japan.
In 2023, the US maintained the largest market share among the 7MM, reaching USD 140 million. Projections indicate that this trend will persist, with the US expected to further strengthen its market dominance and remain the leading player by 2034.
In 2023, Germany and the UK in the EU4 and the UK both achieved market shares exceeding USD 20 million, with France following closely behind. In contrast, Italy had the smallest market share among these regions during the same period.
Opioid analgesics dominated the current treatment market for both inpatient and outpatient care, with an estimated market value of approximately USD 130 million in 2023.
In 2023, the US recorded over 2 million incident cases of burns, with numbers expected to rise by 2034.
In 2023, approximately 0.4 million treated incident burn cases requiring pain management therapies were reported in the US, with expectations for change during the study period from 2020 to 2034.
The gender distribution indicates a male dominance across the 7MM, with around 0.29 million male cases and 0.26 million female cases reported in the US in 2023.
Key Burn Pain Companies: Medical Developments International, Cumberland Pharmaceuticals, Janssen Research & Development, Cephalon, and others
Key Burn Pain Therapies: Methoxyflurane (PENTHROX), Caldolor, JNJ-42160443, ACTIQ, and others
The Burn Pain epidemiology based on etiology-specific cases analyzed that Etiology Specific Incident Cases of Burns is classified into Flame, Contact, Scald, Electrical, Chemical, and Others
The Burn Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Burn Pain pipeline products will significantly revolutionize the Burn Pain market dynamics.
Burn Pain Overview
An organic tissue injury known as a burn is mostly brought on by heat, radiation, radioactivity, electricity, friction, or chemical contact.
Get a Free sample for the Burn Pain Market Report -
Burn Pain Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Burn Pain Epidemiology Segmentation:
The Burn Pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Burn Pain
Prevalent Cases of Burn Pain by severity
Gender-specific Prevalence of Burn Pain
Diagnosed Cases of Episodic and Chronic Burn Pain
Download the report to understand which factors are driving Burn Pain epidemiology trends @ Burn Pain Epidemiology Forecast
Burn Pain Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Burn Pain market or expected to get launched during the study period. The analysis covers Burn Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Burn Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Burn Pain Therapies and Key Companies
Burn Pain Market Strengths
The increasing incidence of patients with burns is expected to propel the treatment market in the future, adding opportunities for new pharma players
Burn Pain Market Opportunities
The rising incidence of burn pain indicates increasing pharmacological treatment demands, thereby crafting lucrative opportunities for new pharma players
Scope of the Burn Pain Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Burn Pain Companies: Medical Developments International, Cumberland Pharmaceuticals, Janssen Research & Development, Cephalon, and others
Key Burn Pain Therapies: Methoxyflurane (PENTHROX), Caldolor, JNJ-42160443, ACTIQ, and others
Burn Pain Therapeutic Assessment: Burn Pain current marketed and Burn Pain emerging therapies
Burn Pain Market Dynamics: Burn Pain market drivers and Burn Pain market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Burn Pain Unmet Needs, KOL's views, Analyst's views, Burn Pain Market Access and Reimbursement
Table of Contents
1. Burn Pain Market Report Introduction
2. Executive Summary for Burn Pain
3. SWOT analysis of Burn Pain
4. Burn Pain Patient Share (%) Overview at a Glance
5. Burn Pain Market Overview at a Glance
6. Burn Pain Disease Background and Overview
7. Burn Pain Epidemiology and Patient Population
8. Country-Specific Patient Population of Burn Pain
9. Burn Pain Current Treatment and Medical Practices
10. Burn Pain Unmet Needs
11. Burn Pain Emerging Therapies
12. Burn Pain Market Outlook
13. Country-Wise Burn Pain Market Analysis (2020–2034)
14. Burn Pain Market Access and Reimbursement of Therapies
15. Burn Pain Market Drivers
16. Burn Pain Market Barriers
17. Burn Pain Appendix
18. Burn Pain Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
3 days ago
- Cision Canada
FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign®
MOMENCE, Ill., June 5, 2025 /CNW/ -- New research published in the International Journal of Molecular Sciences shows that vitAlign®, a proprietary and comprehensive healthy aging innovation from FutureCeuticals, delivers significant benefits for restoring cellular health and supporting a healthy immune response. The study highlights vitAlign's effectiveness in regulating cellular function and metabolic imbalances associated with immune stressors—from the seasonal cold and flu to more complex environmental and immune-related challenges. Researchers evaluated the impact of a low, 50 mg dose of vitAlign in medically stable adults aged 40–55 recovering from a moderate course of COVID-19, as defined by CDC guidelines. The study compared vitAlign to a 1000 mg dose of Vitamin C, focusing on key markers and processes that directly impact immune and cellular health. Results showed that vitAlign significantly reduced excessive reactive oxygen species (ROS) production in mitochondria and through the NOX2 and iNOS pathways—key mechanisms that influence immune and cellular function. Additionally, researchers observed increased levels of circulating, bioavailable nitric oxide, suggesting support for endothelial function and cardiovascular health. The authors noted that the increase in nitric oxide is likely attributable to vitAlign's ability to regulate multiple pathways of ROS production. Notably, vitAlign delivered measurable effects within 30 minutes, lasting up to three hours. In contrast, Vitamin C, which was used as a positive control, was administered at twenty times the dose and did not demonstrate comparable broad-spectrum activity. "These findings build on over a decade of published clinical research establishing vitAlign as a significant cellular health innovation, now extended directly to immune function," said J. Randal Wexler, FutureCeuticals' General Counsel and Vice President of R&D. "Previously, we've shown that vitAlign improves cellular energy efficiency and helps restore metabolic balance, both acutely and over time." Wexler added, "These new results, which compare favorably to a well-known antioxidant like Vitamin C, reinforce vitAlign's potential as a multi-faceted phytonutrient formula, providing broad support for healthy aging, cardiovascular health, and immune function. Our partners are excited about what this means for product innovation and their customers looking for daily cellular health support." About FutureCeuticals: FutureCeuticals, Inc. is the developer of vitAlign and a leader in the research, development, and manufacture of plant-based powders and extracts for the functional food, beverage, and dietary supplement markets.
Cision Canada
3 days ago
- Cision Canada
BTL Announces Expanded Clearances and Versatility for EMSELLA® Platform
TORONTO, June 5, 2025 /CNW/ -- BTL, a global leader in non-invasive medical solutions, proudly announces expanded Health Canada License for its revolutionary EMSELLA® platform, reinforcing its leadership in pelvic health and intimate wellness. FDA-cleared and Health Canada-licensed for the treatment of urinary incontinence in both men and women, Emsella now also holds an additional Health Canada license and CE-mark certification for enhancing sexual function in patients experiencing somatic sexual arousal disorders caused by weak pelvic floor muscles. Backed by robust clinical outcomes, EMSELLA continues to redefine non-invasive care across pelvic health and sexual function. Key findings include: Sexual Dysfunction Statistics: 76% improvement in sexual satisfaction and desire 1 60% improvement in orgasm quality 1 37% improvement in maintaining erection during intercourse 2 48% improvement in pelvic muscle endurance 3 When compared to other modalities, EMSELLA outperforms significantly: 7x more effective than pelvic floor muscle training "EMSELLA continues to surpass expectations—not just in treating incontinence but in restoring confidence, and overall quality of life," said David Chmel, CEO of BTL North America. "These expanded clearances and clinical outcomes validate what providers and patients have long experienced: EMSELLA delivers meaningful results in a way that's accessible, comfortable, and non-invasive." Shari Caplan, MD, CCFP, FCFP, FAARM, a board-certified expert in functional, integrative , anti-aging, and intimate health said, "We're witnessing a complete shift in how pelvic and sexual health is approached. Patients are achieving results we used to think were only possible with surgery or years of therapy. EMSELLA has become a go-to solution in my practice for urinary control and sexual wellness for both men and women." As the demand for intimate wellness treatments rises, EMSELLA remains uniquely positioned as an effective and versatile tool for addressing some of the most intimate and often under-discussed health concerns. To learn more about EMSELLA, visit About BTL Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. With 350+ patents and over 580 in-house engineers, BTL leverages technology and science to advance medical treatments. Its product portfolio includes , EMSCULPT NEO®, EMFACE®, EXION™, EXOMIND™, EMSELLA®, and others. For more information, visit
Cision Canada
3 days ago
- Cision Canada
Aurora Expands Medical Cannabis Offerings in Australia with the Launch of IndiMed TEMPO 22
NASDAQ| TSX: ACB Canada's Largest Medical Cannabis Company Adds Two New Cultivars to Popular Brand Portfolio in the Australian Market EDMONTON, AB, June 5, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, has expanded their popular IndiMed brand with the launch of IndiMed TEMPO 22, available through the company's subsidiary, MedReleaf Australia. With the same consistent quality and reliable supply, this new 22% THC potency creates a greater range of treatment options available to prescribers. "Expanding our portfolio in the value segment in Australia reinforces our commitment to meet increasingly diversified patient needs with accessible, high-quality medical cannabis options," said Andre Jerome, Executive Vice President of Global Business Development at Aurora. "As a global leader in medical cannabis, we're proud to offer a diverse range of products that reflect both local demand and our dedication to innovation worldwide." IndiMed remains one of the most prescribed medical cannabis brands for patients in Australia. The two new cultivars available include: IndiMed TEMPO 22 | Lemon Laser – Sativa, 22% THC, <1% CBD, Dried Cannabis (15g) IndiMed TEMPO 22 | Pickled Petrol – Indica, 22% THC, <1% CBD, Dried Cannabis (15g) Aurora's continued focus on international growth and deep commitment to providing patients with innovative products and expanded access enables the company to maintain its global leadership position. MedReleaf Australia, a wholly owned subsidiary of Aurora, is committed to quality and proudly meeting all TGA-GMP standards. For further information about the company's offerings, doctors and health care professionals can contact MedReleaf Australia's clinical support team or visit their website: About Aurora Cannabis Inc. Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Contact For Investors: ICR, Inc. | [email protected] Forward Looking Information This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law (" forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding: the expansion of the Company's medical cannabis offerings in Australia and the availability of specific products; the Company's commitment to innovation, quality and expanded access; the Company's continued focus on international growth; and the Company's global leadership position. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
